BLAINJECTIONINJECTABLE
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
NIVESTYM (filgrastim-aafi) by Pfizer is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. Approved for breast cancer, neutropenia. First approved in 2018.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIVESTYM (filgrastim-aafi) is a biosimilar granulocyte colony-stimulating factor (G-CSF) that stimulates neutrophil production by binding to hematopoietic cell surface receptors. It is approved for reducing infection risk in breast cancer patients receiving chemotherapy and for treating neutropenia. The drug works by promoting proliferation, differentiation, and functional activation of neutrophil progenitor cells in the bone marrow.
Peak
NIVESTYM is in peak revenue stage as a Pfizer biosimilar in an established oncology supportive care market; the commercial team likely focuses on maintaining market penetration against entrenched competitors.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Pharmacologic Class:
Leukocyte Growth Factor
Indications (2)
Worked on NIVESTYM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.